TIDMMSYS
RNS Number : 3540Q
Microsaic Systems plc
27 October 2021
Microsaic Systems plc
("Microsaic" or the "Company")
Launch of real-time monitoring workflows and services for
scaling drug manufacture
Microsaic (AIM: MSYS) is pleased to announce the immediate
roll-out of its compact Mass Spectrometry ("MS") technology
integrated with autosampler and separation technology, wrapped in
closed-loop (automated) control software, for use in the scale-up
and operation of drug manufacturing. These monitoring solutions are
targeted at contract research and manufacturing organisations
("CRMO"), integration partners and biopharmaceutical companies who
manufacture vaccines, therapeutics for major diseases such as
chronic autoimmune diseases.
This offering adds turn-key services to the bioprocessing
industry, using compact Microsaic technology for monitoring levels
of metabolites and proteins as part of wider workflows designed
to:
-- increase the efficiency of biotherapeutic development and manufacture;
-- reduce batch failures; and,
-- create the pathway to real-time data and analytics and
[potential] optimisation of biopharmaceutical manufacture.
These solutions can therefore reduce manufacturing scale-up time
and costs, improve quality and reduce the cost of drug manufacture,
while increasing the throughput from discovery and development and
the quantity of approved drugs able to reach the market in the
shortest time possible.
The Company's small-footprint bio-reactor monitoring technology
has already demonstrated the ability to track successfully all key
parameters during biomanufacture (as announced on 2 July 2021),
such as feedstocks, metabolites and now additionally the target
proteins (for example, complex monoclonal antibody therapeutics) in
real-time.
Glenn Tracey, CEO of Microsaic, commented: " The accelerated
development and scale-up of COVID-19 vaccines has shown what can be
achieved by biopharmaceutical manufacturing. It has also emphasised
the need to find ways to develop and manufacture life-changing
drugs and therapies on a large scale, both quickly and reliably.
These new monitoring solutions bring potentially game-changing
capabilities to monitor the material aspects of bioproduction, in
real time and at the point of need, and to address these critical
manufacturing needs. Additionally, Microsaic brings its expertise
in workflow customisation, set up, and software control and
analytics.
"This extension to our range of MS equipment and solutions to
cover biologic molecules, alongside other gains in detection
sensitivity, immediately widens the opportunities for revenues from
multiple sectors in biopharmaceuticals, healthcare and
environmental industries. We expect workflow service and
installations to begin in H1 2022."
Background to Microsaic's Bioprocessing Solutions:
Directly interfaced with a bioreactor and autosampler,
Microsaic's micro-engineered and fully portable MS detector has now
been integrated with process control software. This enables
continuous, real-time analysis of the biomanufacturing process,
including the provision of additional data analytics for quality
monitoring, process optimisation and assurance.
Biopharmaceuticals is a well-established and rapidly growing
sector (valued at circa $200 billion in a 2020 report(1) ), which
faces significant challenges around process robustness. This is
particularly apparent within upstream processing, which relies on
fundamental biology and carries inherent product variability.
Continuous point-of-need MS would provide timely and critical
safety and quality assurance, as adverse effects would be
identified earlier in the process and mitigated upstream.
The analytical instrumentation market in upstream bioprocessing
alone was projected to be worth circa $390 million in 2020(2) . The
Company believes that its compact, easy-to-use, MS technology is
well-positioned to access a share of this market, working with
bioprocessing instrument providers, CRMOs and end-users in
biopharmaceutical manufacturing alike.
(1) 2020 Global Life Sciences Outlook , Deloitte
(2) Report on upstream bioprocessing analytical instrumentation,
TDA consultants 2019
Enquiries:
Microsaic Systems plc
Glenn Tracey, CEO - Bevan Metcalf,
FD +44 (0)1483 751 577
Singer Capital Markets
(Nominated Adviser & Joint Broker) +44 (0)20 7496 3000
Aubrey Powell / George Tzimas (Investment
Banking)
Turner Pope Investments (TPI) Limited
(Joint Broker)
Andy Thacker / James Pope +44 (0) 20 3657 0050
About Microsaic ( www.microsaic.com )
Microsaic listed on AIM in 2011 to develop and commercialise
micro-engineering chip-based mass spectrometry equipment. Having
invested GBP30m over the last 20 years before and after the IPO,
Microsaic has a robust patent portfolio in cutting-edge technology
purpose built for "Industry 4.0" which enables analytical detection
and characterisation at the point-of-need, whether within a human
health environment, conventional laboratory setting, or within a
bioprocessing facility for continuous mass spectrometer detection
and monitoring of data at any step in the process workflow.
Microsaic's products and systems are commercially available
through global markets via a network of regional and local
partners, targeting its core laboratory, manufacturing, and
point-of-need applications.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDGBDGLXDDGBL
(END) Dow Jones Newswires
October 27, 2021 02:00 ET (06:00 GMT)
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From Apr 2024 to May 2024
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From May 2023 to May 2024
